截至9月30日，雷电微力股东户数3.55万，较上期减少7.02%；人均流通股5852股，较上期增加7.55%。 2025年1月-9月，雷电微力实现营业收入6.90亿元，同比减少41.10%；归母净利润1.57亿元，同比减少 58.07%。 11月12日，雷电微力涨0.11%，成交额1.13亿元。两融数据显示，当日雷电微力获融资买入额1392.50万 元，融资偿还1763.25万元，融资净买入-370.75万元。截至11月12日，雷电微力融资融券余额合计6.75 亿元。 融资方面，雷电微力当日融资买入1392.50万元。当前融资余额6.74亿元，占流通市值的6.03%，融资余 额低于近一年10%分位水平，处于低位。 融券方面，雷电微力11月12日融券偿还200.00股，融券卖出1.36万股，按当日收盘价计算，卖出金额 61.62万元；融券余量3.15万股，融券余额142.45万元，低于近一年20%分位水平，处于低位。 资料显示，成都雷电微力科技股份有限公司位于四川省成都市双流区华府大道四段19号，成立日期2007 年9月11日，上市日期2021年8月24日，公司主营业务涉及毫米波有源相控阵微系统研发、制造、测试 ...

Core Viewpoint - The company, 雷电微力, emphasizes a dual approach in its R&D projects, focusing on both customer-driven needs and forward-looking independent research initiatives [1] Group 1 - The company's R&D model is characterized by a combination of demand-driven projects and technological reserves [1] - The primary focus of the R&D efforts is on the low-cost and large-scale application of millimeter-wave micro-system technology [1]

Group 1 - The company acknowledges concerns regarding its market value performance amidst a rising secondary market and emphasizes the importance of investor protection in its operations [1] - The company adheres to the principle that "value creation is core," recognizing that market value fundamentally relies on long-term value accumulation [1] - The company aims to strengthen its long-term value through continuous technological refinement and stable operations, while also enhancing communication with the capital market to clarify its competitiveness and long-term development potential [1]

Core Viewpoint - The company, 雷电微力 (301050.SZ), has indicated that its technology is adaptable to relevant application fields and has already developed products related to synthetic aperture radar [1] Group 1 - The company has confirmed the adaptability of its technology to various application areas [1] - The company has already launched products in the field of synthetic aperture radar [1]

Core Viewpoint - The company LeiDian Micro Power (301050.SZ) currently does not have any consumer-end products [1] Group 1 - The company has clarified its product offerings on the investor interaction platform [1]

Core Viewpoint - 雷电微力 has no plans to expand into the quantum communication field due to differences between its existing core technology and the technology required in that area [1] Company Summary - 雷电微力 stated on its investor interaction platform that there are discrepancies between the technology in the quantum communication sector and its current core technology path [1]

证券代码：301050 证券简称：雷电微力 公告编号：2025-052 成都雷电微力科技股份有限公司 关于召开2025年第三次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 根据成都雷电微力科技股份有限公司（以下简称"公司"）第二届董 事会第十六次会议决议，公司决定于2025年11月13日（星期四）召开2025 年第三次临时股东会，现将本次股东会有关事项通知如下： 一、召开会议的基本情况 1.股东会届次：2025年第三次临时股东会 2.会议召集人：公司董事会 3.会议召开的合法、合规性：本次股东会的召集程序符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》的规定。 4.会议召开的日期、时间 （1）现场会议时间：2025年11月13日（星期四）下午15:00 （2）网络投票时间：2025年11月13日（星期四） 其中，通过深圳证券交易所交易系统进行网络投票的时间为：2025年 11月13日上午9:15-9:25，9:30-11:30，下午13:00-15:00；通过深圳证券 交易所互联网投票系统投票的具体时间为：2025年11月1 ...

Group 1 - Taifu Pump Industry has terminated the acquisition of 51% equity in Nanyang Huacheng [1] - Shareholder Fosun Pharma of Shanhe Pharmaceutical Auxiliary plans to reduce its stake by no more than 3% [1] - Several convertible bonds including Anji Convertible Bond, Longda Convertible Bond, and Oujing Convertible Bond will not undergo forced redemption [1][2] Group 2 - The following convertible bonds will not be adjusted: Oujing Convertible Bond, Longda Convertible Bond, and Tong 22 Convertible Bond [2] - New shares from Danna Biotechnology will be listed on the Beijing Stock Exchange [1] - North Mining Testing is also set to issue new shares on the Beijing Stock Exchange [1]

Core Viewpoint - The recent quarterly performance of the company appears to show growth, but a deeper analysis reveals that this growth is primarily supported by one-time collaboration revenue, raising concerns about the company's long-term profitability and operational status [2][5]. Financial Performance - In Q3, the company reported a revenue of 1.895 billion yuan, a year-on-year increase of 1625.08%, and a net profit of 623 million yuan, up 203.74% year-on-year [2]. - However, the cumulative revenue for the first three quarters was 2.066 billion yuan, a year-on-year decline of 63.52%, with a net profit of -495 million yuan, down 112.16% year-on-year [3]. Revenue Sources - The significant revenue increase in Q3 was largely due to a milestone payment of 250 million USD (approximately 1.895 billion yuan) from a collaboration with Bristol-Myers Squibb, categorized as a one-time license-out revenue with minimal costs [5]. - The high R&D expenses, amounting to 1.77 billion yuan in the first three quarters, accounted for 85.8% of total revenue, indicating that for every 1 yuan of revenue, 0.86 yuan was spent on R&D [5][7]. R&D Challenges - The company is facing a vicious cycle of increasing R&D investment without substantial revenue conversion, as only 3 out of 15 drugs in development have reached Phase III trials [7]. - The high proportion of R&D expenses is attributed to declining revenue rather than an increase in R&D intensity, leading to operational risks [7]. Traditional Business Struggles - The company's traditional products, such as propofol emulsion and astragalus granules, are experiencing revenue declines due to price reductions from national procurement policies and increased competition [9]. - The revenue from propofol emulsion is projected to drop from 314 million yuan in 2022 to 132 million yuan in 2024, with a corresponding decrease in gross margin from 76.77% to 32.32% [9]. - The market penetration of the company's traditional products has decreased from 18% in 2022 to 9% in 2024, facing competition from leading companies like Heng Rui Pharmaceutical and Yangtze River Pharmaceutical [9]. Operational Efficiency Issues - The company is experiencing inventory turnover issues, with inventory turnover days reaching 313.37 days, significantly higher than the industry average of 60-90 days [10]. - There has been a noticeable decline in operational efficiency, with accounts receivable turnover days increasing from 60.65 days in 2021 to 128.4 days by Q3 2025 [10].

Core Viewpoint - 雷电微力 is a leading enterprise in the domestic millimeter-wave active phased array micro-system sector, with core technological advantages and a complete industrial chain capability [1] Group 1: Business Performance - In Q3 2025, 雷电微力 achieved a revenue of 690 million yuan, ranking 27th among 64 companies in the industry, while the top company, 中航成飞, reported revenue of 48.286 billion yuan [2] - The net profit for the same period was 157 million yuan, placing 雷电微力 13th in the industry, with the top company, 中航成飞, reporting a net profit of 2.175 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, 雷电微力's debt-to-asset ratio was 17.77%, down from 20.82% year-on-year and significantly lower than the industry average of 32.84% [3] - The gross profit margin for the same period was 33.73%, a decrease from 44.03% year-on-year, and slightly below the industry average of 34.84% [3] Group 3: Executive Compensation - The chairman, 桂峻, received a salary of 2.561 million yuan in 2024, an increase of 1.223 million yuan compared to 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.02% to 35,500, while the average number of circulating A-shares held per shareholder increased by 7.55% to 5,852.67 [5]